@highvibemari's compound semaglutide journey, fact-checked

What did @highvibemari actually say?

She reported losing 23.5 pounds over 10 weeks on compounded semaglutide, starting at 196 lbs with a goal of 145 lbs at 5'2". She also described a severe three-day headache after increasing her dose, calling it her worst side effect. Her closing advice: "If you've tried everything else and nothing has worked for you, please give GLP medications a chance."

She also mentioned transitioning from a local weight loss clinic to an online provider because it was "significantly cheaper," and she uses the hashtag #compoundsemaglutide throughout, which is worth unpacking. She does not mention having a PCOS diagnosis explicitly in this clip, though her hashtags and community framing suggest it. The weight loss number, the side effect report, and the provider-switching decision are all worth examining closely.

Does the science back this up?

The weight loss rate she describes is fast but not outside the range seen in clinical trials, particularly in people with PCOS. The headache side effect is real and documented. The "try everything else first" framing, though, is more complicated than she makes it sound.

In the STEP 1 trial (Wilding et al., 2021, NEJM), participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks. Losing roughly 12% in 10 weeks is on the high end but plausible in early treatment when response is strongest. For people with PCOS specifically, a 2023 pilot study (Cena et al., Nutrients) found semaglutide improved both weight and androgen markers. As for headaches, they appear in prescribing information as a reported adverse event, and migraine-like symptoms during dose escalation are documented in post-market surveillance. Her description of a debilitating, eye-squinting headache lasting three days is consistent with what some users report at higher doses, and she was right to flag it.

What did they get wrong (or right)?

She got the side effect disclosure right, and that matters. A lot of GLP-1 content on TikTok skips the bad weeks entirely. Credit where it is due: she came back on camera to report a three-day headache that "wouldn't budge" even with Zofran and electrolytes. That is honest content.

Where she gets fuzzy is the compounded semaglutide switch. She says she found an online provider that is "significantly cheaper" and she is "very confident" in them, but she gives no information about how to evaluate a compounded semaglutide provider. Compounded semaglutide is not the same as FDA-approved branded semaglutide. The FDA has flagged compounded versions as carrying quality and dosing risks (FDA Drug Shortages guidance, 2024). Switching providers mid-treatment without clinical oversight is also not a trivial decision. Her framing of it as a simple cost optimization glosses over real safety considerations. She also does not clarify whether her online provider involves any physician oversight, which is a meaningful gap for 86,000 viewers who might do the same thing.

What should you actually know?

GLP-1 receptor agonists like semaglutide do have a real evidence base for weight loss, including in people with PCOS. The results she is seeing are not implausible. But several things in this video deserve a second look before you apply her experience to yourself.

• Compounded semaglutide is not interchangeable with brand-name Wegovy or Ozempic. Compounded versions are not FDA-approved, and potency, purity, and dosing can vary by pharmacy. The FDA updated its guidance on this in 2024 specifically because of safety reports.
• Severe headaches during dose escalation should be reported to your prescriber, not just managed at home with antiemetics. A headache bad enough to close one eye for three days warrants a clinical conversation, not just a shout-out to Zofran.
• Switching GLP-1 providers mid-treatment based on cost alone is a decision that should involve your prescriber. Dose continuity and monitoring matter, especially during escalation phases.
• Her BMI-based goal weight commentary is actually reasonable. She correctly notes that a standard BMI cutoff may not fit her body composition, which aligns with criticism of BMI as a universal health metric (Rothman, 2008, International Journal of Obesity).
• "If you've tried everything else" is not a clinical threshold. GLP-1 medications are prescribed based on BMI, comorbidities, and clinical judgment, not as a last resort after years of failed diets.

The bottom line

Her weight loss results are plausible. Her willingness to report a difficult side effect is genuinely useful. But her framing of compounded semaglutide provider-switching as a simple, safe cost move is the part of this video that 86,000 people should not take at face value. Anyone considering compounded semaglutide through an online provider should verify that a licensed clinician is reviewing their case, not just processing an order. The drug is real. The risks are real. The cost savings are also real. All three things can be true at the same time.